Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17117181 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL12243239 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL16730747 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL19644929 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL17109563 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL15682912 | 0.91 | TMPRSS2 (0.41) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL881677 | 0.90 | TMPRSS2 (0.40) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL15888889 | 0.90 | TMPRSS2 (0.40) | TMPRSS2ADORA2APIK3CDPOLRMTPI4KA | |
| SCHEMBL12393232 | 0.90 | TMPRSS2 (0.37) | TMPRSS2ADORA2APOLRMTPI4KAPI4K2B | |
| SCHEMBL12393404 | 0.89 | TMPRSS2 (0.41) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | INSPIRMED CORP (TW) | 2023-06-15 | — | — | US | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012012465-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | CLARKE, MICHAEL, O'NEIL HANRAHAN (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011150288-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | TMPRSS2 2225/4885ADORA2A 113/4885PIK3CD 377/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | TMPRSS2 1945/4885ADORA2A 93/4885PIK3CD 334/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | TMPRSS2 1426/4885ADORA2A 1055/4885PIK3CD 4557/4885 |
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | LIPA, MAVS, ISG15 | TMPRSS2 2386/4885ADORA2A 581/4885PIK3CD 2045/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | TMPRSS2 1426/4885ADORA2A 1055/4885PIK3CD 4557/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | TMPRSS2 1426/4885ADORA2A 1055/4885PIK3CD 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.